Suppression of Lewis Lung Tumor Development in Alpha 1,3 Galactosyltransferase Knock-Out Mice

Anticancer Research

Volumn 24, Issue 2 B, 2004, Pages 605-612

  Posekany, Karla J ^a   Pittman, H Keith ^a   Swanson, Melvin S ^a   Haisch, Carl E ^a   Verbanac, Kathryn M ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Alpha 1,3 galactosyltransferase; Anti Gal antibodies; Immunotherapy; Tumor antigens

Indexed keywords

ALPHA 1,3 GALACTOSYLTRANSFERASE; ANTIGEN; CELL ANTIBODY; GALACTOSYLTRANSFERASE; IMMUNOGLOBULIN M ANTIBODY; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ALPHA 1,3 GALACTOSYLTRANSFERASE GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; COMPLEMENT DEPENDENT CYTOTOXICITY; CONFERENCE PAPER; CONTROLLED STUDY; GENE; HUMAN; IN VITRO STUDY; KNOCKOUT MOUSE; LEWIS CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIBODIES, NEOPLASM; CARCINOMA, LEWIS LUNG; FEMALE; GALACTOSYLTRANSFERASES; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUNG NEOPLASMS; MALE; MICE; MICE, KNOCKOUT;

EID: 2442491065     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. Larson RD, Rivero-Marrero CA, Ernst LK, Cummings RD and Lowe JB: Frameshift and nonsense mutations in a human genomic sequence homologous to a murine UDP-Gal: β-D-Gal (1,4)-D-GlcNac α (1,3) galactosyl transferase cDNA. J Biol Chem 265: 7055-7061, 1990.
2. Kobayashi T and Cooper DKC: Anti-αGal, α-Gal epitopes, and xenotransplantation. Subcellular Biochemistry 32: 229-257, 1999.
3. Galili U, Mandrell RE, Hamadeh RM, Shohet SB and Grifiss JM: Interaction between human natural anti-a-galactosyl immunoglobin G and bacteria of the human flora. Infect Immun 56: 1730-1737, 1988.
4. Welsh RM, O'Donnell CL, Reed DJ and Rother RP: Evaluation of the Gal α1,3 Gal epitope as a host modification factor eliciting natural humoral immunity to enveloped viruses. J Virol 72: 4650-4656, 1998.
5. Galili U and Andrews P: Suppression of α-galactosyl epitope synthesis and production of the natural anti-αGal antibody: A major evolutionary event in ancestral Old World primates. J Hum Evol 29: 433-442, 1995.
6. McMorrow IM, Comrack CA, Nazary PP, Sachs DH and DerSimonian H: Heterogeneity of human anti-pig natural antibodies cross-reactive with the αGal (1,3) Galactose epitope. Transplantation 64: 501-510, 1997.
7. Vaughan HA, Loveland BE and Sandrin M: Gal α (1,3) gal is the major xenoepitope expressed on pig endothelial cells recognized by naturally occurring cytotoxic human antibodies. Transplantation 58: 879-882, 1994.
8. Kwiatkowski P, Artrip JH, Michler RE, Wang SF, McKenzie IF, Sandrin MS and Itescu S: Human monocytes bind to ligands on porcine endothelium containing the gal alpha (1,3)-Gal antigen. Transplantation Proceedings 32: 931, 2000.
9. Inverardi L, Clissi B, Stolzer AL, Bender JR, Sandrin MS and Pardi R: Human natural killer lymphocytes directly recognize evolutionarily conserved oligosaccharide ligands expressed by xenogeneic tissues. Transplantation 63: 1318-1330, 1997.
10. Gilboa E: How tumors escape immune destruction and what we can do about it. Cancer Immunol Immunother 48: 382-385, 1999.
11. Foss F: Immunologic mechanisms of antitumor activity. Semin Oncol 29: 511, 2002.
12. Pardoll DM: Therapeutic vaccination for cancer. Clin Immunol 95: s44-62, 2000.
13. Nencioni A and Brossart P: New perspectives in dendritic cell-based cancer immunotherapy. BioDrugs 15: 667-79, 2001.
14. Mitchell MS: Cancer vaccines, a critical review-Part I. Curr Opin Investig Drugs 3(1): 140-9, 2002.
15. Reilly RT, Emans LA and Jaffee EM: Humoral and cellular immune responses: Independent forces or collaborators in the fight against cancer? Cur Opin Invest Drugs 2: 133-135, 2001.
16. Takahashi T, Johnson TD, Nishinaka Y, Morton DL and Irie RI: IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients. J. Invest Dermatology 112(2): 205-209, 1999.
17. Maloney DG, Smith B and Rose A: Rituximab: mechanism of action and resistance. Semin Oncol 29: s2-9, 2002.
18. Thall AD, Murphy HS and Lowe JB: α 1,3 Galactosyl-transferase-deficient mice produce naturally occurring cytotoxic anti-αGal antibodies. Transplant. Proc 28: 556-557, 1996.
19. Posekany KJ, Pittman HK, Haisch CE and Verbanac KM: The alpha 1,3 galactosyltransferase mouse is not an innate model for human hyperacute rejection: problems defined and solutions proffered. Transplantation 66: s49, 1998.
20. McKenzie IFC, Thall AD, Sandrin M, Patton K and Li YQ: A murine model of antibody-mediated hyperacute rejection by galactose-α (1,3) galactose antibodies in gal o/o mice. Transplantation 66: 754-763, 1998.
21. Posekany KJ, Pittman HK, Bradfield JF, Haisch CE and Verbanac KM: Induction of cytolytic anti-αGal antibodies in alpha 1,3 galactosyltransferase gene knock-out mice by oral inoculation with Escherichia coli O86.B7 bacteria. Infect Immun 70: 6215-6222, 2002.
22. Chiang TR, Fanget L, Gregory R, Tang Y, Ardiet DL, Gao L, Meschter C, Kozikowski AP, Buelow R and Vuist WM: Anti-αGal antibodies in humans and 1,3 alpha-galactosyl-transferase knock-out mice. Transplantation 27: 2593-2600, 2000.
23. Jager U, Takeuchi Y and Porter CD: Induction of complement attack on human cells by Gal (alpha 1, 3) Gal xenoantigen expression as a gene therapy approach to cancer. Gene Therapy 6: 1073-1083, 1999.
24. Link CJ Jr, Seregina T, Atchison R, Hall A, Muldoon R and Levy JP: Eliciting hyperacute xenograft response to treat human cancer: alpha(1,3) galactosyltransferase gene therapy. Anticancer Res 18(4A): 2301-8, 1998.
25. Isakov N, Shulamit K, Feldman M and Segal S: Loss of expression of transplantation antigens encoded by the H-2K locus on Lewis Lung carcinoma cells and it's relevance to the tumor's metastatic properties. JNCI 71: 139-145, 1983.
26. Cretin N, Bracy J, Hanson K and Iacomini J: The role of T cell help in the production of antibodies specific for Gal alpha 1-3Gal. J Immunol 168(3): 1479-83, 2002.
27. Tanemura M, Dengping Y, Chong AS and Galili U: Differential immune responses to α-gal epitopes on xenografts and allografts: implications for accommodation in xenotransplantation. J Clin Invest 105: 301-310, 2000.
28. Xu H, Yin D, Naziruddin B, Chen I, Stark A, Wei Y, Lei Y, Shen J, Logan JS, Byrne GW and Chong AS: The in vitro and in vivo effects of anti-αGalactose antibodies on endothelial cell activation and xenograft rejection. J Immunol 170(3): 1531-9, 2003.
29. Ragupathi G: Carbohydrate antigens as targets for active specific immunotherapy. Cancer Immunol Immunother 43(3): 152-7, 1996.
30. 3 correlates with tumor growth after immunization with melanoma-cell vaccine with different adjuvants in mice. Int J Cancer 75: 117-124, 1998.
31. Chung MH, Gupta RK, Hsueh E, Essner R, Ye W, Yee R and Morton DL: Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy. Cancer Immunol Immunother 43(3): 152-7, 1996.
32. Sumimoto H, Tani K, Nakazaki Y, Tanabe T, Hibino H, Hamada H, Azuma M and Asano S: GM-CSF and B7-1 (CD80) co-stimulatory signals co-operate in the induction of effective anti-tumor immunity in syngeneic mice. Int J Cancer 73: 556-561, 1997.
33. LaTemple DC, Abrams JT, Zhang SY and Galili U: Increased immunogenicity of tumor vaccines complexed with anti-αGal: Studies in knockout mice for alpha 1,3 galactosyltransferase. Cancer Res 115: 3417-23, 1999.
34. Tanemura M and Galili U: T cells interacting with the alpha-Gal epitope: studies in alpha1, 3 Galactosyltransferase knock-out mice. Transplant Proc 32(5): 921-923, 2000.
35. Tanemura M, Chong AS, DiSesa VJ and Galili U: Direct killing of xenograft cells by CD8+ T cells of discordant xenograft recipients. Transplantation 74(11): 1587-95, 2002.
36. Araneda D, Posekany K, Pittman HK, Haisch CE and Verbanac, KM, unpublished data.